Unique approach to precision medicine could reverse the trend in Alzheimer’s disease drug discovery and development
Clinical trials in Alzheimer’s disease have had a 99% failure rate. It is time for a new approach. Time for some more Precision. Unique combinatorial analytics have identified multiple clear subgroups with druggable biological mechanisms within Alzheimer’s disease patient population, making effective personalized treatments a real possibility for the first time.